Le Lézard
Classified in: Health, Science and technology
Subjects: IPO, Business Update

Citi Appointed as Depositary Bank for Abivax SA's ADR Program


Citi, acting through Citibank N.A., has been appointed by Abivax SA ("Abivax"), to act as depositary bank for its initial public offering (the "IPO") of Abivax's American Depositary Shares ("ADSs" or "ADRs") representing its ordinary shares.

Abivax's ADSs trade on the Nasdaq Global Market under the ticker symbol "ABVX". The company's underlying ordinary shares are listed on Euronext Paris under the symbol "ABVX". Each ADS represents one ordinary share of the company.

Commenting on the appointment, Dirk Jones, Global Head of Issuer Services, at Citi said: "We look forward to supporting Abivax's ADR program and expanding the company's investor outreach through the expertise of our Investor Relations Advisory team and the breadth of our global equity distribution network."

Citi is a leading provider of depositary receipt services. With depositary receipt programs in 67 markets, spanning equity and fixed-income products, Citi leverages its global network to provide cross-border capital market access to issuers, intermediaries, and investors.

For more information on Citi's Depositary Receipt Services, visit www.citi.com/dr .

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.

For more information on Abivax, visit https://www.abivax.com/.

About Citi

Citi is a preeminent banking partner for institutions with cross-border needs, a global leader in wealth management and a valued personal bank in its home market of the United States. Citi does business in nearly 160 countries and jurisdictions, providing corporations, governments, investors, institutions, and individuals with a broad range of financial products and services.

Additional information may be found at www.citigroup.com | Twitter: @Citi | LinkedIn: www.linkedin.com/company/citi | YouTube: www.youtube.com/citi | Facebook: www.facebook.com/citi


These press releases may also interest you

at 00:01
The Novo Nordisk Foundation, Wellcome, and the Bill & Melinda Gates Foundation announced a new partnership to support critical scientific research and development (R&D) for global health. The partnership is focused on supporting science and...

5 mai 2024
The Halal Economy Leadership Forum 2024 (HELF 2024) held recently in Riyadh, Saudi Arabia, set the stage for a momentous gathering of industry leaders, policymakers, and experts to advance discussions on the Halal Economy?a vital cornerstone of...

5 mai 2024
Johnson & Johnson announced today updated results from an open-label, multicenter, multi-cohort Phase 1 study of the safety and efficacy of TAR-210, an intravesical targeted releasing system designed to provide sustained, local release of erdafitinib...

5 mai 2024
UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing novel solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest real-world patient cohort review...

5 mai 2024
The Aesthetic Foundation, formerly known as the Aesthetic Surgery Education and Research Foundation (ASERF), proudly announces the election of Dr. Onelio Garcia Jr. "Oni", as its new President. Dr. Garcia's appointment heralds an exciting chapter for...

5 mai 2024
The Aesthetic Society proudly announces the appointment of Dr. Kiya Movassaghi, a board-certified plastic surgeon from Eugene, OR, as the President of The Aesthetic Society. Dr. Movassaghi's leadership will focus on strategically fortifying The...



News published on and distributed by: